Treatment update: Thiazolidinediones in combination with metformin for the treatment of type 2 diabetes

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 503-510

  Stafford, John M ^a,b   Elasy, Tom ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Metformin; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMILORIDE; ANTILIPEMIC AGENT; ATORVASTATIN; BIGUANIDE; DIGOXIN; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; INSULIN GLARGINE; KETOCONAZOLE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; MIDAZOLAM; MORPHINE; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA; TRIMETHOPRIM; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIET THERAPY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DYSLIPIDEMIA; EDEMA; ENDOTHELIAL DYSFUNCTION; GLUCONEOGENESIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LIPID COMPOSITION; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; REVIEW; SIDE EFFECT; WATER RETENTION; WEIGHT GAIN;

CHROMANS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 35148856230     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Bailey CJ, Turner RC. 1996. Metformm. N Engl J Med, 334:574-9.
2. Balletshofer BM, Rittig K, Enderle MD, et al. 2000. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation, 101:1780-4.
3. Basu A, Jensen MD, McCann F, et al. 2006. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care, 29:510-14.
4. Bergholm R, Tiikkainen M, Vehkavaara S, et al. 2003. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care, 26:1667-72.
5. Betteridge DJ, Verges B. 2005. Long-term effects on lipids and lipoproteins of piogtitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia, 48:2477-81.
6. Bruemmer D, Blaschke F, Law RE. 2005. New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes (Lond), 29(Suppl 1)S26-30.
7. Caballero AE. 2005. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res, 36:241-9.
8. Caldwell SH, Argo CK, Al-Osaimi AM. 2006. Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol, 40:S61-6.
9. Charbonnel B, Schernthaner G, Brunetti P, et al. 2005. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia, 48:1093-4.
10. Chen K, Li F, Li J, et al. 2006. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med, 12:425-32.
11. Chiquette E, Ramirez G, Defronzo R. 2004. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med, 164:2097-104.
12. Dailey GE 3rd, Noor MA, Park JS, et al. 2004. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med, 116:223-9.
13. DeFronzo RA. 2004. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am, 88:787-835, ix.
14. DeFronzo RA, Goldberg M, Agus ZS. 1976. The effects of glucose and insulin on renal electrolyte transport. J Clin Invest, 58:83-90.
15. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. 1985. Effects of insulin on peripheral and splanehnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest, 76:149-55.
16. Delerive P, Martin-Nizard F, Chinetti G, et al. 1999. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res, 85:394-402.
17. Derosa G, Cicero AF, Gaddi A, et al. 2005a. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract, 69:5-13.
18. Derosa G, Cicero AF, Gaddi AV, et al. 2005b. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther, 27:1383-91.
19. Di Cicco RA, Allen A, Carr A, et al. 2000. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol, 40:1280-5.
20. Dormandy JA, Charbonnel B, Eckland DJ, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366:1279-89.
21. Einhorn D, Rendell M, Rosenzweig J, et al. 2000. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther, 22:1395-409.
22. Fonseca V, Rosenstock J, Patwardhan R, et al. 2000. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA, 283:1695-702.
23. Fryer LG, Parbu-Patel A, Carling D. 2002. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem, 277:25226-32.
24. Gastaldelli A, Miyazaki Y, Pettiti M, et al. 2002. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab, 87:5098-103.
25. Gerstein HC, Yusuf S, Bosch J, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368:1096-105.
26. Ginsberg H, Kimmerling G, Olefsky JM, et al. 1975. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest, 55:454-451.
27. GlaxoSmithKline. 2007. Avandamet: summary of product characteristics [online]. URL: http://us.gsk.com/products/assets/us_avandamet.pdf
28. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. 2002. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev, 18:127-34.
29. Granner DK, O'Brien RM. 1992. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care, 15:369-95.
30. Haffner SM, Lehto S, Ronnemaa T, et al. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339:229-34.
31. Haffner SM, Stern MP, Hazuda HP, et al. 1990. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA, 263:2893-8.
32. Hardie DG, Carling D, Carlson M. 1998. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem, 67:821-55.
33. Hawley SA, Davison M, Woods A, et al. 1996. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem, 271:27879-87.
34. Howard BV, Rodriguez BL, Bennett PH, et al. 2002. Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. Circulation, 105, e132-7.
35. Hundal RS, Krssak M, Dufour S, et al. 2000. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 49:2063-9.
36. Inzucchi SE, Maggs DG, Spollett GR, et al. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 338:867-72.
37. Kato K, Satoh H, Endo Y, et al. 1999. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun, 258:431-5.
38. Kendall DM, Rubin CJ, Mohideen P, et al. 2006. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care, 29:1016-23.
39. Kersten S, Desvergne B, Wahli W. 2000. Roles of PPARs in health and disease. Nature, 405:421-4.
40. Kirpichnikov D, McFarlane SI, Sowers JR. 2002. Metformin: an update. Ann Intern Med, 137:25-33.
41. Knowler WC, Barrett-Connor E, Fowler SE, et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403.
42. Large V, Beylot M. 1999. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Diabetes, 48:1251-7.
43. Lee Y, Hirose H, Ohneda M, et al. 1994. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA, 91:10878-82.
44. Lillioja S, Mott DM, Howard BV, et al. 1988. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med, 318:1217-25.
45. Magnusson I, Rothman DL, Katz LD, et al. 1992. Increased rate of gluconeo-genesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest, 90:1323-7.
46. Matthews DR, Charbonnel BH, Hanefeld M, et al. 2005. Long-term therapy with addition o fpioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev, 21:167-74.
47. Mazzone T, Meyer PM, Feinstein SB, et al. 2006. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 296:2572-81.
48. Meigs JB, Larson MG, D'Agostino RB, et al. 2002. Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study. Diabetes Care, 25:1313-9.
49. Meigs JB, Mittleman MA, Nathan DM, et al. 2000. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA, 283:221-8.
50. Miyazaki Y, Mahankali A, Matsuda M, et al. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 87:2784-91.
51. Moller DE. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab, 11:212-7.
52. Natali A, Baldeweg S, Toschi E, et al. 2004. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care, 27:1349-57.
53. Nolan JJ, Ludvik B, Beerdsen P, et al. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med, 331:1188-93.
54. Ovalle F, Bell DS. 2004. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care, 27:2585-9.
55. Perez A, Khan M, Johnson T, et al. 2004. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res, 1:44-50.
56. Perriello G, Misericordia P, Volpi E, et al. 1994. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes, 43:920-8.
57. Pischon T, Girman CJ, Hotamisligil GS, et al. 2004. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 291:1730-7.
58. Polousky KS, Sturis J, Bell GI. 1996. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med, 334:777-83.
59. Roe MW, Worley JF 3rd, Tokuyama Y, et al. 1996. NIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activity. Am J Physiol, 270:E133-40.
60. Rosenstock J, Sugimoto D, Strange P, et al. 2006. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, 29:554-9.
61. Rossetti L, DeFronzo RA, Gherzi R, et al. 1990. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. Metabolism, 39:425-35.
62. Saad MF, Knowler WC, Pettitt DJ, et al. 1988. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med, 319:1500-6.
63. Saad MF, Knowler WC, Pettitt DJ, et al. 1989. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet, 1:1356-9.
64. Samaha FF, Szapary PO, Iqbal N, et al. 2006. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol, 26:624-30.
65. TakedaPharmaceuticals Actosplus Met. Prescribing information [online]. Accessed 25 July 2007. URL: http://www.actos.com/actos/ prescribinginfo.aspx
66. UKPDS. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:854-65.
67. Umpierrez G, Issa M, Vlajnic A. 2006. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin, 22:751-9.
68. Unger RH. 2005. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie, 87:57-64.
69. Weissman P, Goldstein BJ, Rosenstock J, et al. 2005. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin, 21:2029-35.
70. Wilson PW, D'Agostino RB, Parise H, et al. 2005. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation, 112:3066-72.
71. Wilson PW, D'Agostino RB, Sullivan L, et al. 2002. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med, 162:1867-72.
72. Xiang AH, Peters RK, Kjos SL, et al. 2006. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes, 55:517-22.
73. Ye JM, Dzamko N, Cleasby ME, et al. 2004. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia, 47:1306-13.
74. Ye JM, Frangioudakis G, Iglesias MA, et al. 2002. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology, 143:4527-35.
75. Yki-Jarvinen H. 2004. Thiazolidinediones. N Engl J Med, 351:1106-18.